Acid Addition Salts, Hydrates and Polymorphs of 5-(2,4-Dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic Acid Ethylamide and Formulations Comprising These Forms

Abstract

The present invention relates to new salt forms of 5 -(- 2,4 -dihydroxy- 5 -isopropyl-phenyl)- 4 -( 4 -morpholin- 4 -ylmethyl-phenyl)-isoxazole- 3 -carboxylic acid ethylamide, in particular the mesylate, hydrochloride, lartrate, phosphate and hemi fumarate slat thereof; to crystalline forms of such salts; to polymorphs of 5 -( 2,4 -dihydroxy- 5 -isopropyl-phenyl)- 4 -( 4 -morpholin- 4 -ylmethyl-phenyl)-isoxazole- 4 -carboxylic acid ethylamide; to hydrates and polymorphs of the new salt forms mentioned above; to the use of the new salt forms mentioned above for the manufacture of a medicament for the treatment of a disorder mediated by Hsp90; to a method for treating a disorder mediated by Hsp90 using the new salt forms; to formulations comprising such salt forms, in particular aqueous solutions suitable for intravenous administration; and to amber glass containers being filled with such formulations.

What is claimed is: 
     
         1 . A salt which is 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide hydrochloride or a hydrate thereof. 
     
     
         2 . A crystalline form of the salt according to  claim 1 . 
     
     
         3 . A crystalline form according to  claim 2  which shows an X-ray diffraction diagram of the type shown in  FIG. 10 , in which the relative peak intensities of each peak do not deviate by more than 10% of the relative peak intensities in the diagram shown in  FIG. 10 .